Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs

PLoS Neglected Tropical Diseases

Volumn 6, Issue 4, 2012, Pages

  Bell, Andrew S ^a,c   Mills, James E ^a   Williams, Gareth P ^a   Brannigan, James A ^b   Wilkinson, Anthony J ^b   Parkinson, Tanya ^a   Leatherbarrow, Robin J ^c   Tate, Edward W ^c   Holder, Anthony A ^d   Smith, Deborah F ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN N MYRISTOYLTRANSFERASE; PROTEIN N MYRISTOYLTRANSFERASE INHIBITOR; ACYLTRANSFERASE; ANTIPROTOZOAL AGENT; ENZYME INHIBITOR; GLYCYLPEPTIDE N-TETRADECANOYLTRANSFERASE; PROTOZOAL PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; HUMAN; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; SACCHAROMYCES CEREVISIAE; SCREENING; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA BRUCEI; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; PROTOZOAL INFECTION; PUBLIC-PRIVATE PARTNERSHIP; TROPIC CLIMATE;

ACYLTRANSFERASES; ANTIPROTOZOAL AGENTS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; LEISHMANIA DONOVANI; MOLECULAR STRUCTURE; PLASMODIUM FALCIPARUM; PROTOZOAN INFECTIONS; PROTOZOAN PROTEINS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; STRUCTURE-ACTIVITY RELATIONSHIP; TROPICAL CLIMATE; TRYPANOSOMA BRUCEI BRUCEI;

EID: 84861212906     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001625     Document Type: Article

References (47)

1. TDR: For Research on Diseases of Poverty. http://apps.who.int/tdr/.
2. TDR: Leishmaniasis. http://www.who.int/tdr/diseases/leish/diseaseinfo.htm.
3. den Boer M, Argaw D, Jannin J, Alvar J, (2011) Leishmaniasis impact and treatment access. Clin Microbiol Infect 17: 1471-1477.
4. Sundar S, (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849-854.
5. den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M, (2009) Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs 14: 395-410.
6. WHO (2011) World Malaria Report. http://www.who.int/entity/malaria/world_malaria_report_2011/en/index.html.
7. Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, et al. (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. The Lancet 379: 413-431.
8. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, et al. (2007) Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 79-87.
9. Wellems TE, Plowe CV, (2001) Chloroquine-resistant malaria. J Infect Dis 184: 770-776.
10. Bloland PB, (2001) Drug Resistance in Malaria. WHO/CDS/DRS4: WHO.
11. WHO (2010) Guidelines for the Treatment of Malaria 2nd Edition.
12. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S, (2004) Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 3: 509-520.
13. White NJ, (1999) Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41: 301-308.
14. Foundation BaMG.http://www.gatesfoundation.org.
15. Sakata T, Winzeler EA, (2007) Genomics, systems biology and drug development for infectious diseases. Mol Biosyst 3: 841-848.
16. Patel V, Booker M, Kramer M, Ross L, Celatka CA, et al. (2008) Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 283: 35078-35085.
17. Beghyn TB, Charton J, Leroux F, Laconde G, Bourin A, et al. (2011) Drug to genome to drug: discovery of new antiplasmodial compounds. J Med Chem 54: 3222-3240.
18. Oduor RO, Ojo KK, Williams GP, Bertelli F, Mills J, et al. (2011) Trypanosoma brucei Glycogen Synthase Kinase-3, A Target for Anti-Trypanosomal Drug Development: A Public-Private Partnership to Identify Novel Leads. PLoS Negl Trop Dis 5: e1017.
19. Gelb MH, Van Voorhis WC, Buckner FS, Yokoyama K, Eastman R, et al. (2003) Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Molecular and Biochemical Parasitology 126: 155-163.
20. Ohtsuka T, Aoki I, (2003) N-Myristoyltransferase inhibitors as potential antifungal drugs. Drugs of the Future 28: 143-152.
21. Yamazaki K, Kaneko Y, Suwa K, Ebara S, Nakazawa K, et al. (2005) Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure. Bioorg Med Chem 13: 2509-2522.
22. Frearson JA, Brand S, McElroy SP, Cleghorn LAT, Smid O, et al. (2010) N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464: 728-732.
23. Brand S, Cleghorn LAT, McElroy SP, Robinson DA, Smith VC, et al. (2011) Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry.
24. Panethymitaki C, Bowyer PW, Price HP, Leatherbarrow RJ, Brown KA, et al. (2006) Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major. Biochem J 396: 277-285.
25. Price HP, Guther ML, Ferguson MA, Smith DF, (2010) Myristoyl-CoA:protein N-myristoyltransferase depletion in trypanosomes causes avirulence and endocytic defects. Mol Biochem Parasitol 169: 55-58.
26. Price HP, Menon MR, Panethymitaki C, Goulding D, McKean PG, et al. (2003) Myristoyl-CoA:protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites. J Biol Chem 278: 7206-7214.
27. Bowyer PW, Gunaratne RS, Grainger M, Withers-Martinez C, Wickramsinghe SR, et al. (2007) Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum. Biochem J 408: 173-180.
28. Gunaratne RS, Sajid M, Ling IT, Tripathi R, Pachebat JA, et al. (2000) Characterization of N-myristoyltransferase from Plasmodium falciparum. Biochem J 348 Pt 2: 459-463.
29. Wright M, Heal W, Mann D, Tate E, (2010) Protein myristoylation in health and disease. Journal of Chemical Biology 3: 19-35.
30. Bowyer PW, Tate EW, Leatherbarrow RJ, Holder AA, Smith DF, et al. (2008) N-myristoyltransferase: a prospective drug target for protozoan parasites. ChemMedChem 3: 402-408.
31. Sogabe S, Masubuchi M, Sakata K, Fukami TA, Morikami K, et al. (2002) Crystal Structures of Candida albicans N-Myristoyltransferase with Two Distinct Inhibitors. Chemistry & Biology 9: 1119-1128.
32. McWherter CA, Rocque WJ, Zupec ME, Freeman SK, Brown DL, et al. (1997) Scanning Alanine Mutagenesis and De-peptidization of a Candida albicans Myristoyl-CoA:ProteinN-Myristoyltransferase Octapeptide Substrate Reveals Three Elements Critical for Molecular Recognition. Journal of Biological Chemistry 272: 11874-11880.
33. Bhatnagar RS, Futterer K, Farazi TA, Korolev S, Murray CL, et al. (1998) Structure of N-myristoyltransferase with bound myristoylCoA and peptide substrate analogs. Nat Struct Biol 5: 1091-1097.
34. Devadas B, Freeman SK, McWherter CA, Kishore NS, Lodge JK, et al. (1998) Novel biologically active nonpeptidic inhibitors of myristoylCoA:protein N-myristoyltransferase. J Med Chem 41: 996-1000.
35. Bell AS, (2001) Discovery of fungicidal N-myristoyl transferase inhibitors. 221st ACS National Meeting. San Diego, CA, United States.
36. Yeap SK, Walley RJ, Mason JS, (2005) Maximizing the coverage and flexibility of a diverse representative subset for screening variable number of compounds to suit target knowledge. 230th ACS National Meeting,. Washington, DC.
37. Giang DK, Cravatt BF, (1998) A second mammalian N-myristoyltransferase. J Biol Chem 273: 6595-6598.
38. Yang SH, Shrivastav A, Kosinski C, Sharma RK, Chen MH, et al. (2005) N-myristoyltransferase 1 is essential in early mouse development. J Biol Chem 280: 18990-18995.
39. Goncalves V, Brannigan JA, Thinon E, Olaleye TO, Serwa R, et al. (2012) A fluorescence-based assay for N-myristoyltransferase activity. Anal Biochem 421: 342-344.
40. Brannigan JA, Smith BA, Yu Z, Brzozowski AM, Hodgkinson MR, et al. (2010) N-Myristoyltransferase from Leishmania donovani: Structural and Functional Characterisation of a Potential Drug Target for Visceral Leishmaniasis. Journal of Molecular Biology 396: 985-999.
41. Hertz-Fowler C, Ersfeld K, Gull K, (2001) CAP5.5, a life-cycle-regulated, cytoskeleton-associated protein is a member of a novel family of calpain-related proteins in Trypanosoma brucei. Mol Biochem Parasitol 116: 25-34.
42. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
43. Glick M, Klon AE, Acklin P, Davies JW, (2004) Enrichment of extremely noisy high-throughput screening data using a naive Bayes classifier. J Biomol Screen 9: 32-36.
44. Posner BA, Xi H, Mills JEJ, (2009) Enhanced HTS Hit Selection via a Local Hit Rate Analysis. Journal of Chemical Information and Modeling 49: 2202-2210.
45. Kuntz ID, Chen K, Sharp KA, Kollman PA, (1999) The maximal affinity of ligands. Proc Natl Acad Sci U S A 96: 9997-10002.
46. Hopkins AL, Groom CR, Alex A, (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9: 430-431.
47. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL, (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815.